|会社名||Sorrento Therapeutics Inc （ソレント・セラピュ―ティクス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Commercial Physical_Biological Resarch|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 Sorrento Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in the discovery acquisition development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs resiniferatoxin (RTX) and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs) including biosimilars/biobetters fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform antibody drug conjugates (ADCs) bispecific antibodies (BsAbs) as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy. ソレント・セラピュ―ティクスは米国のバイオ医薬品会社。慢性的な痛みを伴うがん、免疫疾患、感染病などの治療薬の発見・買収・商業化に従事。主要な製品候補には、がんを対象とするミセルジブロック共重合体パクリタキセル製剤「Cynviloq」がある。同社のパイプラインには、臨床前段階のヒト治療抗体も含む。本社はサンディエゴ。 Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.|
|本社所在地||4955 Directors Place San Diego CA 92121 USA|
|代表者氏名||Henry H. Ji Henry H. Ji|
|代表者役職名||President Chief Executive Officer Director 社長兼最高経営責任者（CEO）|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Sorrento Therapeutics Inc revenues increased 6% to $10.2M. Net loss increased from $37.3M to $106.4M. Revenues reflect Sales and services increase from $4.5M to $9.9M. Higher net loss reflects Interest Expense increase from $2.8M to $46.1M (expense) Loss (gain) on contingent liabilities an increase from $4.1M (income) to $13.7M (expense) Research and development increase of 25% to $32.6M (expense).|
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Could See A Rise In Prices Shortly. 2022/08/01 15:30:00 Marketing Sentinel
In the last trading session, 5.56 million shares of the Sorrento Therapeutics Inc. (NASDAQ:SRNE) were traded, and its beta was 2.23. Most recently the company’s share price was $2.60, and it changed around -$0.02 or -0.76% from the last close, which brings the market valuation of the company to $1.03B. SRNE currently trades at a … Sorrento Therapeutics Inc. (NASDAQ: SRNE) Could See A Rise In Prices Shortly. Read More »
Increasing unusual put option volume: TIP CLVS TEN TSM MXEA DM SRNE 2022/08/01 14:49:03 Investing.com
10 Stocks to Sell Before They Die 2022/07/29 17:29:40 InvestorPlace
This article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks, subscribe to his mailing list here . Source: Shutterstock Growing up, my family’s hamburger grilling looked like this. Ground beef? Check. Salt, pepper and spices? Of course. Then add bell peppers, onions, saltine crackers and an egg for good measure? Umm… That too. It was only after the internet came around did I learn we weren’t supposed to turn our burger patties into wads of meatloaf. Many of the world’s top chefs create award-winning concoctions with only three ingredients: ground beef, salt and pepper. The amateur practice of overdoing things extends to investing too. There’s always a temptation to have 30… 50… 100 open positions to avoid the feeling of missing out. And rather than shine, these gargantuan portfolios eventually look like a bland mishmash of uninspiring ingredients. Getting Rich Without Really Trying The secret to winning portfolios, of course, is to concentrate bets in a handful of high-conviction positions.
FDA Clears Sorrento''s STI-1558 Phase 1 Study To Treat COVID-19 Infection 2022/07/20 14:41:58 Benzinga
The FDA has signed off Sorrento Therapeutics Inc''s (NASDAQ: SRNE ) Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic function. The Phase 1 study will examine the PK in patients with moderate renal and hepatic impairment. Using a cross-over design, two doses of STI-1558 (300 mg and 600 … Full story available on Benzinga.com
SRNE stock gains as FDA clears Phase 1 trial for COVID-19 therapeutic (NASDAQ:SRNE) 2022/07/19 19:39:39 Seeking Alpha
San Diego, California-based biotech Sorrento Therapeutics (SRNE) traded higher on Tuesday after the company announced that the U.S
Financial Review: Sorrento Therapeutics (NASDAQ:SRNE) & Alector (NASDAQ:ALEC) 2021/11/04 05:24:42 Dakota Financial News
Sorrento Therapeutics (NASDAQ:SRNE) and Alector (NASDAQ:ALEC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability. Profitability This table compares Sorrento Therapeutics and Alectors net margins, return on equity and return on assets. 
Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Expected to Post Quarterly Sales of $10.21 Million 2021/11/04 04:30:41 Dakota Financial News
Wall Street brokerages expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report $10.21 million in sales for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics earnings. The lowest sales estimate is $3.51 million and the highest is $16.90 million. Sorrento Therapeutics reported sales of $11.75 million in the same quarter 
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Analysts Prediction On How Much It Could Rise 2021/11/03 11:30:00 Stocks Register
The trading price of Sorrento Therapeutics Inc. (NASDAQ:SRNE) closed lower on Tuesday, November 02, closing at $6.95, -1.42% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer 2021/11/01 13:00:00 Intrado Digital Media
SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee''s Pharmaceutical Holdings Limited (Lee''s Pharma, HKEX: 950) has submitted a NDA (new drug application) for the anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory to treat recurrent or metastatic cervical cancer. The NDA application has been accepted by China NMPA.
-$0.21 Earnings Per Share Expected for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) This Quarter 2021/10/28 16:03:34 Dakota Financial News
Equities research analysts expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to report earnings of ($0.21) per share for the current quarter, according to Zacks. Two analysts have made estimates for Sorrento Therapeutics earnings, with the lowest EPS estimate coming in at ($0.29) and the highest estimate coming in at ($0.17). Sorrento Therapeutics posted earnings per share of 
Sorrento Therapeutics forms Mexico subsidiary in COVID-19 product development push 2021/07/20 19:49:49 Seeking Alpha
Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento''s Portfolio of COVID-19 Products in Mexico and Parts of Latin America 2021/07/20 19:29:06 Benzinga
Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico. Sorrento''s Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units. Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrento''s portfolio of products for the Mexican and potentially other Latin American Markets. SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE , ", Sorrento", )) today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico ("Sorrento Mexico"), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories. Sorrento Mexico has established offices in Mexico City with Dr.
Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrentos Portfolio of COVID-19 Products in Mexico and Parts of Latin America 2021/07/20 19:29:00 Intrado Digital Media
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.
Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management 2021/07/20 16:53:00 Intrado Digital Media
PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced complete enrollment of SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 ソレント・セラピュ―ティクス SRNE Sorrento Therapeutics Inc.）